Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Adma Biologics (ADMA) FCF Margin (2016 - 2025)

Historic FCF Margin for Adma Biologics (ADMA) over the last 13 years, with Q3 2025 value amounting to 0.8%.

  • Adma Biologics' FCF Margin fell 208000.0% to 0.8% in Q3 2025 from the same period last year, while for Sep 2025 it was 8.34%, marking a year-over-year decrease of 124000.0%. This contributed to the annual value of 25.9% for FY2024, which is 243400.0% up from last year.
  • Adma Biologics' FCF Margin amounted to 0.8% in Q3 2025, which was down 208000.0% from 15.34% recorded in Q2 2025.
  • Adma Biologics' 5-year FCF Margin high stood at 40.66% for Q2 2024, and its period low was 223.07% during Q1 2021.
  • For the 5-year period, Adma Biologics' FCF Margin averaged around 35.73%, with its median value being 21.23% (2025).
  • Per our database at Business Quant, Adma Biologics' FCF Margin soared by 1891200bps in 2021 and then crashed by -253100bps in 2025.
  • Adma Biologics' FCF Margin (Quarter) stood at 67.53% in 2021, then skyrocketed by 67bps to 22.26% in 2022, then soared by 200bps to 22.19% in 2023, then soared by 82bps to 40.37% in 2024, then tumbled by -102bps to 0.8% in 2025.
  • Its FCF Margin was 0.8% in Q3 2025, compared to 15.34% in Q2 2025 and 21.23% in Q1 2025.